 Cyclin-Dependent Kinase 4
"Cyclin-Dependent Kinase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 4 is a key regulator of G1 PHASE of the CELL CYCLE. It partners with CYCLIN D to phosphorylate RETINOBLASTOMA PROTEIN. CDK4 activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P16.
| Descriptor ID |
D051358
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.875 D12.644.360.250.451 D12.776.167.200.451 D12.776.476.250.451
|
| Concept/Terms |
Cyclin-Dependent Kinase 4- Cyclin-Dependent Kinase 4
- Cyclin Dependent Kinase 4
- Cdk4 Cyclin-Dependent Kinase
- Cdk4 Cyclin Dependent Kinase
- Cyclin-Dependent Kinase, Cdk4
- Cdk4 Protein
- Cdk4 Protein Kinase
- Protein Kinase, Cdk4
- p34PSK-J3 Kinase
- p34PSK J3 Kinase
- Cell Division Protein Kinase 4
- PSK-J3 Kinase
- PSK J3 Kinase
- Cyclin D-Dependent Kinase CDK4
- Cyclin D Dependent Kinase CDK4
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 4".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 4" by people in this website by year, and whether "Cyclin-Dependent Kinase 4" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2002 | 0 | 4 | 4 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 4 | 2 | 6 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 1 | 3 | | 2016 | 5 | 1 | 6 | | 2017 | 6 | 3 | 9 | | 2018 | 2 | 2 | 4 | | 2019 | 3 | 0 | 3 | | 2020 | 4 | 3 | 7 | | 2021 | 1 | 2 | 3 | | 2022 | 1 | 3 | 4 | | 2023 | 1 | 2 | 3 | | 2024 | 4 | 2 | 6 | | 2025 | 3 | 2 | 5 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 4" by people in Profiles.
-
Knudsen ES, Witkiewicz AK, Kabraji S. The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. Nat Rev Drug Discov. 2026 Jul; 25(7):516-533.
-
O'Connor TN, Schultz E, Kabraji S, Levine E, Williams AJ, Knudsen ES, Witkiewicz AK. Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precis Oncol. 2026 Jan; 10:e2500346.
-
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. PLoS One. 2025; 20(12):e0323235.
-
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415.
-
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Clin Cancer Res. 2025 Oct 15; 31(20):4244-4254.
-
Zheng ZY, Chen A, Jaehnig EJ, Anurag M, Lei JT, Feng L, Wang C, Fandino D, Singh P, Kennedy H, Yadav G, Vollert CT, Tsai J, Chen X, Li Y, Lim B, Thompson A, Li S, Foulds CE, Zhang B, Ellis MJ, Chang EC. NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Witkiewicz AK, Wang J, Schultz E, O'Connor TN, O'Connor T, Levine E, Knudsen ES. Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer. Oncogene. 2025 May; 44(19):1387-1399.
-
Wu J, Wang J, O'Connor TN, Tzetzo SL, Gurova KV, Knudsen ES, Witkiewicz AK. Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models. Mol Cancer Ther. 2024 Dec 03; 23(12):1801-1814.
-
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
Lingo JJ, Voigt E, Quelle DE. Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors. Oncotarget. 2024 09 30; 15:638-643.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|